Skip to main content

Emergent BioSolutions

Protecting You From Public Health Threats

Our mission is to protect and enhance life

Emergent BioSolutions

Prepare. Prevent. Protect.

video link

We make medical countermeasures that address natural, accidental and intentional public health threats. Our products target biological and chemical threats, as well as emerging infectious diseases. 

Strengthening Our Anthrax Franchise

Emergent BioSolutions Completes Acquisition of Raxibacumab from GlaxoSmithKline

Expanding Our Portfolio of Medical Countermeasures

Emergent BioSolutions Completes Acquisition of ACAM2000 Vaccine Business from Sanofi

FDA Approves Manufacturing of ACAM2000 at Canton, Massachusetts Facility

ACAM2000 is the Only FDA-Licensed Smallpox Vaccine 

Analyst & Investor Day 2017

Emergent BioSolutions will host an Analyst & Investor Day in New York City on Thursday, December 7, 2017.

Explore more stories Scroll down